Corcept Therapeutics Incorporated. Forecast, price target & analysts
Corcept Therapeutics Incorporated. Target price 2025 - Analyst rating & recommendation
Corcept Therapeutics Incorporated. Classifications & Recommendation:
Corcept Therapeutics Incorporated. Price Target
| Target Price | $140.25 |
| Price | $83.59 |
| Potential |
67.78%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Corcept Therapeutics Incorporated. 2026 .
The average Corcept Therapeutics Incorporated. target price is $140.25.
This is
67.78%
register free of charge
$152.15
82.01%
register free of charge
$122.21
46.20%
register free of charge
|
|
| A rating was issued by 11 analysts: 9 Analysts recommend Corcept Therapeutics Incorporated. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Corcept Therapeutics Incorporated. stock has an average upside potential 2026 of
67.78%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 675.04 | 836.81 |
| 39.94% | 23.96% | |
| EBITDA Margin | 20.41% | 13.45% |
| 9.13% | 34.09% | |
| Net Margin | 20.92% | 12.43% |
| 4.93% | 40.58% |
7 Analysts have issued a sales forecast Corcept Therapeutics Incorporated. 2025 . The average Corcept Therapeutics Incorporated. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Corcept Therapeutics Incorporated. EBITDA forecast 2025. The average Corcept Therapeutics Incorporated. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Corcept Therapeutics Incorporated. Analysts have issued a net profit forecast 2025. The average Corcept Therapeutics Incorporated. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.24 | 0.99 |
| 30.53% | 20.16% | |
| P/E | 84.49 | |
| EV/Sales | 10.00 |
8 Analysts have issued a Corcept Therapeutics Incorporated. forecast for earnings per share. The average Corcept Therapeutics Incorporated. EPS is
This results in the following potential growth metrics and future valuations:
Corcept Therapeutics Incorporated....
Current Corcept Therapeutics Incorporated. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| UBS |
Locked
➜
Locked
|
Locked | Dec 16 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 25 2025 |
| Wolfe Research |
Locked
➜
Locked
|
Locked | Nov 18 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 20 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 10 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Sep 25 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Sep 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
UBS:
Locked
➜
Locked
|
Dec 16 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 25 2025 |
|
Locked
Wolfe Research:
Locked
➜
Locked
|
Nov 18 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 20 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 10 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Sep 25 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Sep 10 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
